NASDAQ:ABAX

Abaxis Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$83.00
0.00 (0.00 %)
(As of 08/1/2018)
Add
Compare
Today's Range
$83.00
$83.00
50-Day Range N/A
52-Week Range
$43.66
$83.98
VolumeN/A
Average Volume167,754 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Abaxis (NASDAQ:ABAX) Vs. ABT, MDT, ISRG, SYK, BDX, and BSX

Should you be buying ABAX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Abaxis, including Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), and Boston Scientific (BSX).

Abbott Laboratories (NYSE:ABT) and Abaxis (NASDAQ:ABAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Institutional & Insider Ownership

72.6% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 90.2% of Abaxis shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 4.3% of Abaxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Abbott Laboratories and Abaxis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Abaxis0000N/A

Abbott Laboratories presently has a consensus target price of $125.8125, suggesting a potential upside of 5.78%. Given Abbott Laboratories' higher probable upside, research analysts plainly believe Abbott Laboratories is more favorable than Abaxis.

Profitability

This table compares Abbott Laboratories and Abaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
AbaxisN/AN/AN/A

Earnings and Valuation

This table compares Abbott Laboratories and Abaxis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.62$3.69 billion$3.2436.71
AbaxisN/AN/AN/AN/AN/A

Abbott Laboratories has higher revenue and earnings than Abaxis.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Abaxis pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Abbott Laboratories has increased its dividend for 49 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Abbott Laboratories beats Abaxis on 8 of the 11 factors compared between the two stocks.

Abaxis (NASDAQ:ABAX) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Institutional & Insider Ownership

90.2% of Abaxis shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 4.3% of Abaxis shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Abaxis and Medtronic's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbaxisN/AN/AN/AN/AN/A
Medtronic$28.91 billion5.92$4.79 billion$4.5927.65

Medtronic has higher revenue and earnings than Abaxis.

Dividends

Abaxis pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 1.8%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Medtronic has raised its dividend for 44 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Abaxis and Medtronic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abaxis0000N/A
Medtronic031912.91

Medtronic has a consensus price target of $125.8462, suggesting a potential downside of 0.83%. Given Medtronic's higher probable upside, analysts plainly believe Medtronic is more favorable than Abaxis.

Profitability

This table compares Abaxis and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbaxisN/AN/AN/A
Medtronic12.69%9.71%5.30%

Summary

Medtronic beats Abaxis on 9 of the 12 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Abaxis (NASDAQ:ABAX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

86.5% of Intuitive Surgical shares are held by institutional investors. Comparatively, 90.2% of Abaxis shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 4.3% of Abaxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Intuitive Surgical and Abaxis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical081202.60
Abaxis0000N/A

Intuitive Surgical presently has a consensus target price of $806.0556, indicating a potential downside of 3.44%. Given Intuitive Surgical's higher possible upside, analysts plainly believe Intuitive Surgical is more favorable than Abaxis.

Valuation and Earnings

This table compares Intuitive Surgical and Abaxis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion22.07$1.38 billion$9.9583.90
AbaxisN/AN/AN/AN/AN/A

Intuitive Surgical has higher revenue and earnings than Abaxis.

Profitability

This table compares Intuitive Surgical and Abaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
AbaxisN/AN/AN/A

Summary

Intuitive Surgical beats Abaxis on 6 of the 8 factors compared between the two stocks.

Abaxis (NASDAQ:ABAX) and Stryker (NYSE:SYK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

90.2% of Abaxis shares are owned by institutional investors. Comparatively, 71.5% of Stryker shares are owned by institutional investors. 4.3% of Abaxis shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

Abaxis pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 1.0%. Stryker pays out 30.5% of its earnings in the form of a dividend. Stryker has increased its dividend for 1 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation & Earnings

This table compares Abaxis and Stryker's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbaxisN/AN/AN/AN/AN/A
Stryker$14.88 billion6.48$2.08 billion$8.2630.99

Stryker has higher revenue and earnings than Abaxis.

Profitability

This table compares Abaxis and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbaxisN/AN/AN/A
Stryker12.35%20.94%8.77%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abaxis and Stryker, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abaxis0000N/A
Stryker061302.68

Stryker has a consensus target price of $265.00, indicating a potential upside of 3.52%. Given Stryker's higher probable upside, analysts plainly believe Stryker is more favorable than Abaxis.

Summary

Stryker beats Abaxis on 9 of the 11 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Abaxis (NASDAQ:ABAX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Becton, Dickinson and and Abaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
AbaxisN/AN/AN/A

Earnings and Valuation

This table compares Becton, Dickinson and and Abaxis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.19$874 million$10.2024.18
AbaxisN/AN/AN/AN/AN/A

Becton, Dickinson and has higher revenue and earnings than Abaxis.

Dividends

Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. Abaxis pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. Becton, Dickinson and has increased its dividend for 50 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of current recommendations for Becton, Dickinson and and Abaxis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and05602.55
Abaxis0000N/A

Becton, Dickinson and presently has a consensus target price of $280.2222, indicating a potential upside of 13.62%. Given Becton, Dickinson and's higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Abaxis.

Institutional & Insider Ownership

83.2% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 90.2% of Abaxis shares are owned by institutional investors. 0.8% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 4.3% of Abaxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Becton, Dickinson and beats Abaxis on 8 of the 11 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Abaxis (NASDAQ:ABAX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Institutional & Insider Ownership

90.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 90.2% of Abaxis shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 4.3% of Abaxis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Boston Scientific and Abaxis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific041312.83
Abaxis0000N/A

Boston Scientific currently has a consensus target price of $46.2778, suggesting a potential upside of 7.00%. Given Boston Scientific's higher probable upside, equities research analysts plainly believe Boston Scientific is more favorable than Abaxis.

Profitability

This table compares Boston Scientific and Abaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.77%5.57%
AbaxisN/AN/AN/A

Valuation & Earnings

This table compares Boston Scientific and Abaxis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion5.72$4.70 billion$1.5827.37
AbaxisN/AN/AN/AN/AN/A

Boston Scientific has higher revenue and earnings than Abaxis.

Summary

Boston Scientific beats Abaxis on 8 of the 9 factors compared between the two stocks.


Abaxis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$118.94flat$211.33 billion$31.90 billion62.93
Medtronic logo
MDT
Medtronic
2.7$126.90flat$171.07 billion$28.91 billion48.44
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$834.79flat$98.85 billion$4.48 billion95.08
Stryker logo
SYK
Stryker
2.0$255.98flat$96.44 billion$14.88 billion55.53Dividend Announcement
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.2$246.63flat$71.66 billion$17.12 billion90.34Earnings Announcement
Analyst Revision
Boston Scientific logo
BSX
Boston Scientific
2.0$43.25flat$61.44 billion$10.74 billion16.57
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$90.40flat$56.20 billion$4.35 billion72.32
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$525.26flat$44.79 billion$2.41 billion91.51Earnings Announcement
Baxter International logo
BAX
Baxter International
1.9$86.49flat$43.49 billion$11.36 billion49.14
DexCom logo
DXCM
DexCom
2.1$342.69flat$33.14 billion$1.48 billion141.61
ResMed logo
RMD
ResMed
1.5$193.21flat$28.12 billion$2.96 billion41.46
Teleflex logo
TFX
Teleflex
2.0$407.64flat$19.05 billion$2.60 billion52.46
STERIS logo
STE
STERIS
2.1$207.64flat$17.72 billion$3.03 billion42.12Upcoming Earnings
Hologic logo
HOLX
Hologic
2.3$65.09flat$16.68 billion$3.78 billion15.50
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07flat$16.26 billion$3.17 billion60.43
Insulet logo
PODD
Insulet
1.6$226.75flat$15.01 billion$738.20 million515.35Analyst Revision
Abiomed logo
ABMD
Abiomed
1.6$282.72flat$12.79 billion$840.88 million62.14
Masimo logo
MASI
Masimo
1.8$216.88flat$11.93 billion$937.84 million56.33
Hill-Rom logo
HRC
Hill-Rom
2.0$109.27flat$7.26 billion$2.88 billion32.91Dividend Announcement
Analyst Report
Globus Medical logo
GMED
Globus Medical
1.6$71.05flat$7.09 billion$785.37 million77.23Earnings Announcement
Analyst Revision
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$73.68flat$6.23 billion$1.52 billion109.97
NuVasive logo
NUVA
NuVasive
1.2$68.68flat$3.53 billion$1.17 billion-312.18Earnings Announcement
Analyst Revision
AtriCure logo
ATRC
AtriCure
1.5$73.46flat$3.35 billion$230.81 million-63.88
Integer logo
ITGR
Integer
1.6$92.00flat$3.03 billion$1.26 billion41.82
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.41flat$1.38 billion$236.54 million-52.14Earnings Announcement
Alphatec logo
ATEC
Alphatec
1.0$14.02flat$1.36 billion$113.43 million-12.75Earnings Announcement
CryoLife logo
CRY
CryoLife
1.6$29.50flat$1.15 billion$276.22 million-77.63
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.13flat$882.11 million$264.16 million-5.17
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.31flat$825.55 million$459.95 million35.26
Surmodics logo
SRDX
Surmodics
1.5$54.16flat$751.09 million$94.86 million677.00
Accuray logo
ARAY
Accuray
2.0$4.32flat$402.89 million$382.93 million30.86
Invacare logo
IVC
Invacare
1.7$7.99flat$275.05 million$927.96 million-6.50Earnings Announcement
Analyst Downgrade
Analyst Revision
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.92flat$86.41 million$61.30 million-2.15Upcoming Earnings
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.